Pharmasaga

Pharmasaga is a dynamic biotech company focused on pharmaceutical manufacturing and dedicated to advancing innovative solutions for diabetes treatment. As an Academia Sinica-derived enterprise founded in January 2021, Pharmasaga leverages cutting-edge research to develop impactful therapies. The company's core technology revolves around the inhibitor of PX protein, a critical factor in diabetes development, stemming from over 20 years of dedicated research by Dr. Yang at Academia Sinica. Pharmasaga is committed to the commercialization of this groundbreaking technology.

Located at No.99, Lane 130, Sec. 1, Academia Rd., Rm. 443, Building A, Taipei City, TW, Pharmasaga is positioned to make significant strides in the pharmaceutical industry. With a strong foundation in scientific research and a clear focus on diabetes treatment, Pharmasaga is poised for continued growth and success. The company's innovative approach and dedication to improving patient outcomes drive its mission to deliver effective and accessible pharmaceutical solutions.

Pharmasaga is rapidly evolving, and comprehensive details regarding our extended range of products and services will be available soon, enriched with insights directly from our management team. We invite the manager of Pharmasaga to create a customized and exclusive company showcase and product listing on our platform, enhancing visibility and engagement.